Faecal screening of colorectal cancer

International Journal of Clinical Practice

Volumn 62, Issue 3, 2008, Pages 454-459

  Loganayagam, A ^a,b  

^a King's College Hospital ^*  (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA MARKER;

ARTICLE; CANCER SCREENING; CHROMOSOMAL INSTABILITY; CLINICAL TRIAL; COLORECTAL CANCER; DNA METHYLATION; FECES ANALYSIS; HUMAN; MICROSATELLITE INSTABILITY; OCCULT BLOOD; PATIENT COMPLIANCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE;

AGED; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DNA METHYLATION; DNA, NEOPLASM; HUMANS; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; OCCULT BLOOD; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 38849121964     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01532.x     Document Type: Article

References (30)

1. Winawer S, Fletcher R, Rex D et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003 123 : 544 60.
2. Osborn NK, Ahlquist DA. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 2005 128 : 192 206.
3. Grady WM. Epigenetic events in the colorectum and in colon cancer. Biochem Soc Trans 2005 33 : 684 8.
4. Albaugh GP, Iyengar V, Lohani A. Isolation of exfoliated colonic epithelial cells, a novel non-invasive approach to the study of cellular markers. Int J Cancer 1992 52 : 347 50.
5. Brenner DE, Rennert G. Fecal DNA biomarkers for the detection of colorectal neoplasia: attractive, but is it feasible J Natl Cancer Inst 2005 97 : 1107 9.
6. Pignone M, Rich M, Teutsch SM et al. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002 137 : 132 41.
7. Kristinsson J, Nygaard K, Aadland E et al. Screening of first degree relatives of patients operated for colorectal cancer: evaluation of faecal calprotectin vs hemoccult II. Digestion 2001 64 : 104 10.
8. Tibble J, Sigthorsson G, Foster R et al. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001 49 : 402 8.
9. Kronborg O, Ugstad M, Fuglerud P et al. Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 2000 46 : 795 800.
10. Roseth A, Kristinsson J, Nygaard E. Faecal lactoferrin. A novel marker of colorectal cancer in rats, longitudinal in vivo study. Gastroenterology 1995 108 : 530.
11. Dubrow R, Yannieli L. Faecal protein markers of colorectal cancer. Am J Gastroenterol 1992 87 : 854 8.
12. Nakayama T, Yasuoka H, Kishino T et al. ELISA for occult faecal albumin. Lancet 1987 1 : 1368 69.
13. Miyoshi H, Ohshiba S, Asada S et al. Immunological determination of fecal hemoglobin and transferrin levels: a comparison with fecal occult blood tests. Am J Gastroenterol 1992 87 : 67 73.
14. Kim Y, Lee S, Park S et al. Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen. Ann Clin Lab Sci 2003 33 : 32 8.
15. Tonus C, Neupert G, Sellinger M. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. World J Gastroenterol 2006 12 : 7007 11.
16. Davies RJ, Freeman A, Morris LS et al. Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet 2002 359 : 1917 19.
17. Davidson LA, Lupton JR, Miskovsky E et al. Quantification of human intestinal gene expression profiles using exfoliated colonocytes: a pilot study. Biomarkers 2003 8 : 51 61.
18. Ahlquist DA. Molecular stool screening for colorectal cancer. BMJ 2000 321 : 255 6.
19. Fearon ER, Vogelstein B. A genetic model for tumorigenesis. Cell 1990 61 : 759 67.
20. Boland CR. Molecular genetics of hereditary nonpolyposis colorectal cancer. Ann N Y Acad Sci 2000 910 : 50 9.
21. Dong SM, Traverso G, Johnson C et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001 93 : 858 65.
22. Mak T, Lalloo F, Evans DG, Hill J. Molecular stool screening for colorectal cancer. Br J Surg 2004 91 : 790 800.
23. Ahlquist DA, Skoletsky JE, Boynton KA et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000 119 : 1219 27.
24. Sidransky D, Tokino T, Hamilton SR et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumours. Science 1992 256 : 102 5.
25. Ahlquist DA, Shuber AP. Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clin Chim Acta 2002 315 : 157 68.
26. Agrawal J, Syngal S. Colon cancer screening strategies. Curr Opin Gastroenterol 2005 21 : 59 63.
27. Imperiale TF, Ransohoff DF, Itzkowitz SH et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004 351 : 2704 14.
28. Half EE, Lynch PM. Mutated DNA in the stool-does it have a role in colorectal cancer screening. Gastroenterol Hepatol 2006 3 : 594 5.
29. Muller HM, Oberwalder M, Fiegl H et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening Lancet 2004 363 : 1283 85.
30. Song K, Ladabaum U. Potential cost-effectiveness of molecular stool marker testing compared to conventional colorectal cancer (CRC) screening methods. Gastroenterology 2003 124 : A603.